<SEC-DOCUMENT>0001493152-22-023939.txt : 20230901
<SEC-HEADER>0001493152-22-023939.hdr.sgml : 20230901
<ACCEPTANCE-DATETIME>20220824152218
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001493152-22-023939
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20220824

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMPACT BIOMEDICAL INC.
		CENTRAL INDEX KEY:			0001834105
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				853926944
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		200 CANAL VIEW BLVD
		STREET 2:		SUITE 104
		CITY:			ROCHESTER
		STATE:			NY
		ZIP:			14623
		BUSINESS PHONE:		585 232 1500

	MAIL ADDRESS:	
		STREET 1:		200 CANAL VIEW BLVD
		STREET 2:		SUITE 104
		CITY:			ROCHESTER
		STATE:			NY
		ZIP:			14623
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="form-corresp_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
24, 2022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
Securities &amp; Exchange Commission</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Division
of Corporation Finance</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office
of Life Sciences</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100
F Street, N.E.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Washington
D.C. 20549</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Re:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Impact
    BioMedical, Inc.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amendment
    No. 4 to Registration Statement on Form S-1</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Filed
    August 2, 2022</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>File
    No. 333-253037</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
behalf of Impact BioMedical, Inc. (the &ldquo;Company&rdquo;), this letter responds to comments provided by the staff of the Division
of Corporation Finance (the &ldquo;Staff&rdquo;) of the Securities and Exchange Commission (the &ldquo;Commission&rdquo;) to the undersigned
on August 11, 2022, regarding the amendment to the Company&rsquo;s Registration Statement on Form S-1, which was filed with the Commission
on August 2, 2022 (&ldquo;Amendment No. 4&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
substance of the Staff&rsquo;s comments has been restated below in bold/italicized text. The Company&rsquo;s responses to the Staff&rsquo;s
comments are set out immediately under the restated comment. An amendment to the Registration Statement that reflects changes made in
response to the Staff&rsquo;s comments, along with changes made to update certain other information in the Registration Statement, has
also been filed on this date (&ldquo;Amendment No. 5&rdquo;). Unless otherwise indicated, defined terms used herein have the meanings
set forth in Amendment No. 5.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Amendment
No. 4 to Form S-1 filed August 2, 2022</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Summary</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Business
Overview, page 2</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>1.</I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
    note your response to our prior comment 1 and reissue in part. Please expand your Summary to provide examples of material risks and
    uncertainties that are specific to your business. Please include the following:</I></B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>that
    you cannot guarantee that you will find third-parties or customers that are interested in purchasing, licensing, or co-developing
    these products;</I></B></FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/75% Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1185
Avenue of the Americas <B>|</B> 31<SUP>st</SUP> Floor <B>|</B> New York, NY <B>|</B> 10036</FONT></P>

<P STYLE="font: 10pt/75% Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">T
(212) 930 9700 <B>|</B> F (212) 930 9725 <B>|</B> WWW.SRF.LAW</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>that
    even if you are able to establish licensing arrangements, that you cannot guarantee that the licensor will be successful in their
    development efforts;</I></B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>that
    you cannot guarantee that these products will ever be approved for clinical testing or commercialization by the FDA;</I></B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>that
    you have not yet generated any revenue from your operations; and</I></B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;information
    regarding your history of net losses, negative class flows, and accumulated deficit over the last two years.</I></B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Response:
The Company notes the Staff&rsquo;s comment and respectfully advises the Staff that the Company has revised the Registration Statement
to include the following disclosure in Amendment No. 5:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<I><U>Our
business is subject to numerous risks described in the section entitled &ldquo;Risk Factors&rdquo; and elsewhere in this prospectus.
You should carefully consider these risks. Some of these risks include, but are not limited to that:</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>we
    cannot guarantee that we will find third-parties or customers that are interested in purchasing, licensing, or co-developing our
    products;</U></I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>even
    if we are able to establish licensing arrangements, we cannot guarantee that licensors will be successful in their development efforts
    of products;</U></I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>we
    cannot guarantee that our products will ever be approved for clinical testing or commercialization by the FDA;</U></I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>we
    have not yet generated any revenue from our operations; </U></I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>we
    have a history of net losses, negative cash flows, and accumulated deficits over the last two years; and</U></I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>an
    occurrence of an uncontrolled event such as the Covid-19 pandemic, is likely to negatively affect our operations.</U></I>&rdquo;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>2.</I></B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
                                            have reviewed your revisions and response to our prior comment 2. In your response you state
                                            that DSS PureAir, Inc. is not a subsidiary of the company, but in Note 4 to your financial
                                            statements for the quarter ended March 31, 2022 you indicate that DSS PureAir, Inc. is a
                                            wholly owned subsidiary of the company. Please reconcile your response with your disclosure
                                            and revise your disclosure as appropriate, including revising your subsidiary chart. We also
                                            note your disclosure in Note 4 that subsequent to the execution of the promissory note that
                                            DSS PureAir, Inc. entered into a distribution agreement with the Borrower. Please revise
                                            your disclosure to clarify the current status and role of DSS PureAir, Inc. in your company.</I></B></FONT></TD></TR></TABLE>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Response:
The Company notes the Staff&rsquo;s comment and respectfully advises the Staff that DSS PureAir, Inc. was a subsidiary of the Company
when the financial statements for the quarter ended March 31, 2022 were prepared. Subsequent to the financial statements,
DSS PureAir, Inc. was transferred from Impact Biolife Science, Inc. to DSS BioHealth Holdings, Inc., along with its assets and liabilities
on June 1, 2022. Accordingly, DSS PureAir, Inc. is no longer part of the Company&rsquo;s corporate structure.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt/75% Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1185
Avenue of the Americas <B>|</B> 31<SUP>st</SUP> Floor <B>|</B> New York, NY <B>|</B> 10036</FONT></P>

<P STYLE="font: 10pt/75% Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">T
(212) 930 9700 <B>|</B> F (212) 930 9725 <B>|</B> WWW.SRF.LAW</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>3.</I></B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
                                            note your response to our prior comment 4 and reissue. To the extent that VanXin, Quantum,
                                            and CRST 1 are material to your business, please expand your disclosure in your Business
                                            section to provide a more fulsome discussion of these program and a description of development
                                            activities conducted. In your description of each product, please discuss the mechanism of
                                            action, the development activities you have conducted, and the remaining steps to commercialize
                                            the product. Alternatively, please remove these programs from your Summary on page 4.</I></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Response:
The Company notes the Staff&rsquo;s comment and respectfully advises the Staff that the Company has revised the Registration Statement
to replace the disclosures regarding VanXin, Quantum, and CRST 1 with the following disclosure in Amendment No. 5:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<I><U>Though
not of substantive material impact to our business currently, we have three additional products; VanXin, Quantum, and CRST1, which we
believe to have high potentiality of viability and commercialization. VanXin is a natural food preservative booster made up of natural
occurring compounds that can extend the shelf life of various products. Quantum, our Patent Cliff solution, uses advanced methods to
increase effectiveness and persistence of natural compounds and existing drugs, while maintaining the safety attributes of the original
molecules. CRST 1 is our advanced adjuvant for next generation vaccine applications. We intend to commercialize these future portfolio
products through partnerships with large manufactures in the pharmaceutical, food, health and beauty, and nutraceutical industries. We
will leverage their product development, commercialization, and distribution capabilities to take products to market through a licensing
and/or private label sales model.</U></I>&rdquo;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>4.</I></B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
                                            note your revision in response to our prior comment 5 and reissue. There are still statements
                                            of efficacy throughout your disclosure. For example only and without limitation, we note
                                            your statement on page 4 that &ldquo;The testing for CRST 1 has been completed to prove its
                                            effectiveness as a cancer inhibiting agent&rdquo; and your statements on pages F-8 and F-22
                                            that &ldquo;Equivir is a patented medication, that has broad antiviral efficacy against multiple
                                            types of infectious disease.&rdquo; Efficacy and safety are determinations that are solely
                                            within the authority of the FDA. Please remove these and all other statements of efficacy.</I></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Response: The Company notes the Staff&rsquo;s
comment and respectfully advises the Staff that the Company has revised the Registration Statement to remove statements of
efficacy in Amendment No. 5.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations Fiscal Year Ended December 31, 2021, compared to Year Ended
December 31, 2020 Income tax benefit, page 24</U></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/75% Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1185
Avenue of the Americas <B>|</B> 31<SUP>st</SUP> Floor <B>|</B> New York, NY <B>|</B> 10036</FONT></P>

<P STYLE="font: 10pt/75% Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">T
(212) 930 9700 <B>|</B> F (212) 930 9725 <B>|</B> WWW.SRF.LAW</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>5.</I></B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
                                            note from your revised disclosures in response to prior comment 11 that the increase in your
                                            income tax benefit is a direct result of the increase in loss from operations for the year.
                                            Given your disclosures on page F-15 that you believe that it is probable that the Company
                                            would not use tax assets in the near future, please explain why you have not recorded a full
                                            valuation allowance on your deferred tax assets. Please tell us how you considered the guidance
                                            of ASC paragraphs 740-10-30-21 to 23.</I></B></FONT></TD></TR><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
                                                                                                          <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Response:
                                            The Company notes the Staff&rsquo;s comment and respectfully advises the Staff that the Company
                                            has significant deferred tax liabilities in excess of its deferred tax assets (net deferred
                                            tax liabilities).&nbsp; We considered the reversal of these deferred tax liabilities (intangible
                                            assets) over their 15 year amortizable life and scheduled them out against the available
                                            net operating losses, which have an indefinite life.&nbsp; The future taxable income resulting
                                            from the DTL reversals was viewed as sufficient positive evidence to absorb the NOLs.&nbsp;
                                            The increase in the VA shown for 2021 was due to losses incurred in 2021 at non-consolidated
                                            (income tax) subsidiaries that do not have this future income stream.</P>
</TD></TR>
                                                                                                          </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Business,
page 27</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>6.</I></B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
                                            note your response to our prior comment 14 and reissue. Given the early stage of these products,
                                            these claims appear speculative. Please provide context and support to explain your basis
                                            for the claims that &ldquo;natural compounds used in the Linebacker platform have demonstrated
                                            strong potential in treating and preventing a range of diseases . . .&rdquo; and that &ldquo;use
                                            of Laetose in a daily diet, compared to sugar, could result in 30% less sugar consumption
                                            and lower glycemic index/load.&rdquo; Please also describe any discovery activities you have
                                            conducted for these and your other product candidates. To the extent that these claims are
                                            the opinions or belief of management, please revise your statements to clearly characterize
                                            them as such and provide appropriate support for these opinions/beliefs.</I></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Response:
The Company notes the Staff&rsquo;s comment and respectfully advises the Staff that the Company has revised the Registration Statement
to include the following disclosure in Amendment No. 5:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<I><U>Natural compounds used in the Linebacker platform may have potential in
treating and preventing a range of diseases by inhibiting TNF-alpha and indication specific causes (e.g., neurology, anti-inflammatory
diseases, oncology).</U></I>&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<I><U>Use of Laetose in a daily diet, compared to sugar, could potentially result
in less sugar consumption and lower glycemic index/load.</U></I>&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Equivir,
page 30</U></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>7.</I></B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
                                            note your response to our prior comment 16. Please revise your disclosure to provide the
                                            basis for your belief regarding the potential mechanism of action for Equivir.</I></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Response:
The Company notes the Staff&rsquo;s comment and respectfully advises the Staff that the Company has revised the Registration Statement
to include the following disclosure in Amendment No. 5:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<I><U>Equivir
is designed to work by impeding virulence while also blocking multiple methods used by viruses to infect and replicate in host cells,
following deployment in a manner similar to a vitamin, and this intended use is subject to FDA regulation.</U></I>&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>GRDG
Licensing Proceeds Distribution Agreement, page 32</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt/75% Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1185
Avenue of the Americas <B>|</B> 31<SUP>st</SUP> Floor <B>|</B> New York, NY <B>|</B> 10036</FONT></P>

<P STYLE="font: 10pt/75% Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">T
(212) 930 9700 <B>|</B> F (212) 930 9725 <B>|</B> WWW.SRF.LAW</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>8.</I></B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
                                            note your revisions in response to our prior comment 24 and reissue in part. We note that
                                            the GRDG Licensing Proceeds Distribution Agreement provides for monthly &ldquo;Consulting
                                            Payments&rdquo; of $43,325.68 and certain termination provisions. Please expand your description
                                            of the GRDG agreement to disclose the Consulting Payments, the aggregate amount of payments
                                            that Impact has made to date under this agreement, and the termination provisions. Please
                                            also make clear in your description of this agreement and the Global BioLife Stockholders&rsquo;
                                            Agreement that the $43,000 payments to GRDG are the same, singular payment obligation.</I></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Response:
The Company notes the Staff&rsquo;s comment and respectfully advises the Staff that the Company has revised the Registration Statement
to include the following disclosure in Amendment No. 5:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<I><U>GRDG
Licensing Proceeds Distribution Agreement</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>On
February 15, 2022, the Company entered into a Licensing Proceeds Distribution Agreement (the &ldquo;Licensing Agreement&rdquo;) with
GRDG Sciences, LLC (&ldquo;GRDG&rdquo;), Global BioLife, Inc., and Impact BioLife Sciences, Inc., pursuant to which GRDG will receive
20% of the gross licensing or sale proceeds received by the Company from the licensing of improvements with patent and patent applications
(the &ldquo;Improvements&rdquo;), and all research and technology, developed, made, owned, conceived, by GRDG in exchange for funding
from the Company for research and technology development activities. Pursuant to the Licensing Agreement, Impact continues to receive
consulting payments (the &ldquo;Consulting Payments&rdquo;) in the amount of $43,324.68 per month for the purpose of paying or reimbursing
certain salaries, overhead, office rent reimbursement, and other operating costs. As of August 2022, the Company not made any payments
under the Licensing Agreement.</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>The
term of the Licensing Agreement is from February 15, 2022, through the later of (1) the date of the last to expire of a valid patent
of intellectual property, or (2) the date of the last license or fee income generated from the Improvements. The Licensing Agreement
provides for termination for cause, which includes failure to make payment when due, unauthorized disclosure of confidential information,
and unauthorized assignment of the agreement. The parties may terminate the Licensing Agreement with or without cause by providing the
other party with at least two months advance written of a notice of intention of termination.</U></I>&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Intellectual
Property, page 35</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>9.</I></B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
                                            note your revisions in response to our prior comment 18, including your statement that the
                                            expiration date of pending patents typically approximate 20 years from filing. For each of
                                            your pending patents, please disclose the date that you filed your patent application for
                                            each jurisdiction in which you filed. The timeframe in which your intellectual property protections,
                                            granted and pending, expire is material to investors.</I></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Response:
The Company notes the Staff&rsquo;s comment and respectfully advises the Staff that the Company has revised the table of Intellectual
Property in Amendment No. 5 to include a footnote for each pending patent to disclose its respective application filing date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Item
11 - Change in Auditors, page 48</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>10.</I></B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
                                            note your revisions in response to our prior comment 21. Please file a letter from your former
                                            accountant stating whether it agrees with the statements you made in response to this Item.
                                            Refer to Item 304(a)(3) and Item 601(b)(16) of Regulation S-K.</I></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Response: The Company notes the
Staff&rsquo;s comment and respectfully advises the Staff that the Company has filed a letter from Freed Maxick CPAs, P.C. as Exhibit
16.1 to Amendment No. 5.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sincerely,</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Darrin
    M. Ocasio, Esq.</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/75% Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1185
Avenue of the Americas <B>|</B> 31<SUP>st</SUP> Floor <B>|</B> New York, NY <B>|</B> 10036</FONT></P>

<P STYLE="font: 10pt/75% Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">T
(212) 930 9700 <B>|</B> F (212) 930 9725 <B>|</B> WWW.SRF.LAW</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>form-corresp_001.jpg
<TEXT>
begin 644 form-corresp_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !Q 'L# 2(  A$! Q$!_\0
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M05R7Q!_Y!UC_ -?(_D:ZU/\ 5K]!717G*=*$I;Z_H<=!)8FHEVC^3/)/%_\
MR-=__O+_ .@"L2O5M1\&:;J=_+>3O<"64@L$< < #T]JK#X?:..LET?^V@_P
MKD.T\RKJO >G37&N"^"D06RL"_8L1C _,FNJA\"Z%$P9H))<=I)21^5=!!;P
MVL"PP1)%$@P%08 H DKE/B7_ ,DYUK_KB/\ T):U[;7K&]U>33K5_-DB0O(Z
M_='.,9[FK6HZ=::M836-]"L]K,-LD;=&&<_TJH2Y9)OH)JZL?(]%?2__  K3
MP=_T K?\V_QH_P"%:>#O^@%;_FW^->G]>I]F8>R9\T4]?NUZE\6?"NB>'M*T
MZ72=.BM9);AE=D)^8;<XY->6K]VNFE452/,B)*SL,/6B@]:*T$3V=[=Z=<BY
ML;J:VG'22%RI_3K^->D^%_C'J%I/%;>(46ZM20INHUVR)[D#AA^1KR^D8@*2
M>F*SJ4H5%:2&I-;'TCX\ECGTC3I8G#QO<*RLIR""I((KL$_U:_05YK>VMQ9?
M#KPS;W>?/01[@>H^4D#\!@5Z4G^K7Z"O+K*U*"\Y?F31_P!YJ>D?R9SVN>+H
M-#U!;22TEE8QB3<C #DD=_I6;_PL>T_Z!UQ_WVM8WQ _Y&-/^O9?_0FKE:Y3
MM/6="\666NSO;I')!.HW!)"/F'?&/2M74;)=1TZ>S>1XQ*I7>AP17BUM<36E
MS'<V[E)HFW(P[&O8-"UF'6],2ZCPL@^66/\ N-W% ''^"["?3/%=[9W*[9(H
M,<="-PP1[&NF\9ZM=:%X0U+4[+9]HMXPR;QD9W <C\:UC9P&^6\V8G5#'O'=
M2<X-<W\2_P#DG.M?]<1_Z$M732<TGW%+9GDW_"X_%GK8_P#?C_Z]'_"X_%GK
M8_\ ?C_Z]<#17M>PI?RHYN>7<Z/Q+XWUCQ9;06^I_9]D#F1/*CVG.,>M<^OW
M:93U^[6D8J*M%$MM[GIOB&+X6>'M7DTM[#4[Z]B_UL=DSR>6?1CN'/TJ[IFD
M_"_5_#FHZW:VM_Y&FH7NXG:198\#.,$X)P.QJ>;PQXR\#>+M7USPO96>L6.I
MRF6:VE;9,I+%B ?J3^G'%27/C:Q\6?#CQE$-,?3-6M;.07MK(HSNVD;LX&>0
M1SSQ7E>TFTK2?W_H=7+'L6-/\&?#G4/"Z>(Q#-!IC1F0RW%PZ;5!(YY]17)P
M:_\ ":SODN+?1-8N88)-PN?*=XL@]2"W(^H_"L[7YG/P8\"V+RM'8W5V5N2.
MF QQG\R?PKZ%LM/LM/TZ*QL[:**TC38D2*-NW'ZTI5)16K;WZARKL<KXA\3>
M&+B'P\FH"ZEBUB0-8F.-ER>,%LX('SBNFU;4[;0]&N]3N]_V:TB,LFP9;:!S
M@5Y9\:'FM=?\#R65J)YXKN0PVX.T2,/+PN>V>E1^+_%7CN\\'ZO;:CX$%E9R
MVLBS7/V]7\I".6P!SCTK/D<HQUT]?,%&*;DEJSI->\0^#I_#-EXPU.WNY+.[
M*PQ,JL'Y+8RH/L:Y?_A.?AIC_D&ZO_X#R?\ Q58OB;_DW/PQ@9/VJ+^<E>A>
M'O$GC6\U*QM-1\#+96#X62[^VH^Q=O!VXR>@_.ATXI7]>HS.U35_A[HQTG[?
M;74*ZI"LT+L'PB$@9?YOEZ\UUET- \#:/=ZZ(Y8[5$4RF)FDW D $ G!ZUYW
M\6-)@UWXF^$M)N2RP7<3Q,4ZC)/(_'%8-]K]_I7@#Q'\/_$3G^TM/B4V4S=+
MB$.I ![X'(]N.U-4DTFAGJNJ_$_P_H^G:5?7*7S0ZG!]HM_*MRYV\?>P>#R*
MYO6?B]X%U;2I]/U&+53:W"[7!M63(R#US70^&=9T_P /_"+1=4U.58K:#382
MQ/))V#"@=R>@%<CX6T34/B;XC3QEXD@\K1;=B-+TYA\K '[[#N,\Y[GV I1C
M%7;Z"+8\+?#H^++;PU]AO?[0N+?[2G[Q]FS!/)SUP*G\4>#?AWX0TG^TM6M+
ME8#(L2B.9V9F/8#/H"?PJO>\?M+:;_V#'_\ 06K-\>:MIOB'XMZ1H6IWMM;Z
M-I ^T79N) J/(0#L.>O&T8]S6BG4;7O/:XN6/8W_  [X$^'_ (HT6#5M,M+A
M[:;<!OG=6!!P01G@\5K#X2^$ /\ CPF_\"'_ ,:Y#X4:M::/XV\0>$K:^ANM
M/FE:\T^6*0,I'&Y01QG!7/\ NFO9JBI5J1E;F8<L>QYS=^%OB+9WUV=$\96T
MEG<2-($U"WW/#N.=JD \#/M]*;I/PL?3_"_B*UN-5-YK6NQ,ES>R)A02#T'7
M&23[^U96F>._B#XBU'5X="T;1IH-/O'MF::5D;AB!_%Z"MWPCX_U/4/%-SX6
M\3:0FFZS%'YR>2^Z.5/;KVYZG//I2?.ET&6+?X<6=Q\-;;PAJ\HG$"G;<1#:
M4?<2&7/<9_'FL*V\%?$O3;0:58^-K0Z<HV1RRVY,Z)TP#@]!TYIU]\0?$GB/
MQ)>:)X#TZUFCL6V7.HW;?NPV<84?4'U)QTIVG?$#Q'H'B>ST#QWIMM +YMEK
MJ%HW[MFSC!'U('8C(XHM/];#-37? &H:U+X2EFUH33:'+YDTTT6&N3\G. >#
M\M=/XGTA]?\ "^IZ1'*L+WEN\*R,,A2PQDBN+\4^.?$,GC;_ (0_PC8VKW\<
M(FGN;QL(@(!X'? (]>O2M;PSJGC6&YNX/%VF626UO 9EO[.3(<CJNWKG&?3I
M[U+4K)L#*U7X97>H?#'2O"::G"D]C,LAN#&2K8+=!G_:_2F+X0^):H%7Q[;@
M 8'^@BLO2O&GQ#\;I<:IX7T_2;?28I6CC6[<F24C!P?0X(]!S7I'AF]UF_T2
M*?7M-CT_4-S+)!')O7@X!!]^N,FG)SCO8#F+SP%JFH^)?"FM7NKPS7&CIBX/
ME$&X;G)&.G6I?B/\-[;QU:V\D4Z6FI6QPEPR;@R'JK#]1Z'ZUW5%1[22::Z
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MPZ[80VK3_;B!F$  D.W?@X.<\D<]J['Q#\,_"OB6_:_OM/*7K??N+>1HG?\
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4Y??^ U,U%% "4^BB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
